Literature DB >> 19687159

Interleukin 18 gene promoter polymorphism: a link between hypertension and pre-hospital sudden cardiac death: the Helsinki Sudden Death Study.

Jussi A Hernesniemi1, Pekka J Karhunen, Niku Oksala, Mika Kähönen, Mari Levula, Riikka Rontu, Erkki Ilveskoski, Olli Kajander, Sirkka Goebeler, Leena E Viiri, Mikko Hurme, Terho Lehtimäki.   

Abstract

AIMS: The interleukin 18 (IL-18) gene has a single nucleotide promoter region (-137) G-to-C polymorphism (rs187238) which leads to attenuated transcriptional activity of the gene and to lower production of pro-atherogenic IL-18. The C allele of this polymorphism is associated with a lower risk of sudden cardiac death (SCD). We examined the process by which this polymorphism alters the risk of SCD and coronary artery disease (CAD) by analysing the interactions between this polymorphism and environmental factors. METHODS AND
RESULTS: TaqMan 5' nuclease assay was used to genotype the study population of the Helsinki Sudden Death Study, comprising medicolegal autopsies of 700 men. According to adjusted logistic regression analysis, there was a significant interaction between IL-18 genotype and hypertension impacting on the risk of SCD due to coronary heart disease (CHD) (P = 0.011) and the severity of autopsy-verified CAD (P = 0.026). Among GG homozygotes, hypertension was a major risk factor for SCD due to CHD [adjusted odds ratio (OR) 3.75 with 95% CI 1.78-7.91, P < 0.001] and hypertension also associated with larger coronary atherosclerotic plaque areas (P = 0.002) and the occurrence of complicated plaques (adjusted OR 8.38 with 95% CI 2.39-29.33, P < 0.001). Among C allele carriers, hypertension was not a significant risk factor for CHD-related SCD or CAD and did not associate with the development of coronary atherosclerotic plaques. According to gene expression analysis of atherosclerotic tissue samples obtained from live patients, hypertension also interacted significantly with IL-18 genotype affecting the expression of IL-18 (P = 0.030) mRNA and interferon-gamma mRNA (P = 0.004).
CONCLUSION: Hypertension interacts with IL-18 gene promoter -137 G/C polymorphism, affecting the risk of SCD and the development of coronary atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19687159     DOI: 10.1093/eurheartj/ehp316

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  10 in total

1.  PPARG, AGTR1, CXCL16 and LGALS2 polymorphisms are correlated with the risk for coronary heart disease.

Authors:  Jianwei Tian; Shunying Hu; Feng Wang; Xuedong Yang; Yuqian Li; Congchun Huang
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Relationships between selected gene polymorphisms and blood pressure sensitivity to weight loss in elderly persons with hypertension.

Authors:  William J Kostis; Javier Cabrera; W Craig Hooper; Paul K Whelton; Mark A Espeland; Nora M Cosgrove; Jerry Q Cheng; Yingzi Deng; Christine De Staerck; Meredith Pyle; Nisa Maruthur; Ingrid Reyes; Cheryl A M Anderson; Jie Liu; John B Kostis
Journal:  Hypertension       Date:  2013-02-25       Impact factor: 10.190

3.  Evaluation of the Role of -137G/C Single Nucleotide Polymorphism (rs187238) and Gene Expression Levels of the IL-18 in Patients with Coronary Artery Disease.

Authors:  Fatemeh Hoseini; Sanaz Mahmazi; Khalil Mahmoodi; Gholam Ali Jafari; Mohammad Soleiman Soltanpour
Journal:  Oman Med J       Date:  2018-03

Review 4.  Interleukin 18 and coronary heart disease: prospective study and systematic review.

Authors:  Barbara J M H Jefferis; Olia Papacosta; Christopher G Owen; S Goya Wannamethee; Steve E Humphries; Mark Woodward; Lucy T Lennon; Andrew Thomson; Paul Welsh; Ann Rumley; Gordon D O Lowe; Peter H Whincup
Journal:  Atherosclerosis       Date:  2011-03-24       Impact factor: 5.162

5.  IL-18 mediates sickle cell cardiomyopathy and ventricular arrhythmias.

Authors:  Akash Gupta; Yu-Dong Fei; Tae Yun Kim; An Xie; Ken Batai; Ian Greener; Haiyang Tang; Sultan Ciftci-Yilmaz; Elizabeth Juneman; Julia H Indik; Guanbin Shi; Jared Christensen; Geetanjali Gupta; Cheryl Hillery; Mayank M Kansal; Devang S Parikh; Tong Zhou; Jason X-J Yuan; Yogendra Kanthi; Peter Bronk; Gideon Koren; Rick Kittles; Julio D Duarte; Joe G N Garcia; Roberto F Machado; Samuel C Dudley; Bum-Rak Choi; Ankit A Desai
Journal:  Blood       Date:  2021-03-04       Impact factor: 25.476

6.  Interleukin-18 Promoter Gene Polymorphisms are not Associated with Myocardial Infarction in Type 2 Diabetes in Slovenia.

Authors:  S Kariž; D Petrovič
Journal:  Balkan J Med Genet       Date:  2011-06       Impact factor: 0.519

Review 7.  Arterial Hypertension and Interleukins: Potential Therapeutic Target or Future Diagnostic Marker?

Authors:  Daniela Maria Tanase; Evelina Maria Gosav; Smaranda Radu; Anca Ouatu; Ciprian Rezus; Manuela Ciocoiu; Claudia Florida Costea; Mariana Floria
Journal:  Int J Hypertens       Date:  2019-05-02       Impact factor: 2.420

Review 8.  Neurological Disorders and Risk of Arrhythmia.

Authors:  Joyce Bernardi; Kelly A Aromolaran; Ademuyiwa S Aromolaran
Journal:  Int J Mol Sci       Date:  2020-12-27       Impact factor: 5.923

9.  Interleukin-18 can predict pre-clinical atherosclerosis and poor glycemic control in type 2 diabetes mellitus.

Authors:  Zhian M Ibrahim Dezayee
Journal:  Int J Appl Basic Med Res       Date:  2011-07

10.  Associations of Single Nucleotide Polymorphisms in IL-18 Gene with Plasmodium falciparum-Associated Malaria.

Authors:  Alaa U AlRuwaisan; Mashael R Al-Anazi; Mohammed I Shafeai; Fuad H Rudiny; Ali M Motaen; Saad M Bin Dajem; Hani Alothaid; Kareem Morsy; Saad Alkahtani; Ahmed A Al-Qahtani
Journal:  J Inflamm Res       Date:  2021-07-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.